Anti-SARS-CoV-2 hyperimmune immunoglobulins, an urgent strategic choice

Author unknown

Open source

DOI: 10.1016/j.banm.2020.05.042
Published: 2020-12
Container: Bulletin de l'Académie Nationale de Médecine
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 58/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.banm.2020.05.042,
  title = {Anti-SARS-CoV-2 hyperimmune immunoglobulins, an urgent strategic choice},
  year = {2020},
  journal = {Bulletin de l'Académie Nationale de Médecine},
  doi = {10.1016/j.banm.2020.05.042},
  url = {https://doi.org/10.1016/j.banm.2020.05.042}
}

RIS

TY  - JOUR
TI  - Anti-SARS-CoV-2 hyperimmune immunoglobulins, an urgent strategic choice
PY  - 2020
JO  - Bulletin de l'Académie Nationale de Médecine
DO  - 10.1016/j.banm.2020.05.042
UR  - https://doi.org/10.1016/j.banm.2020.05.042
ER  -

APA

Anti-SARS-CoV-2 hyperimmune immunoglobulins, an urgent strategic choice. (2020). Bulletin de l'Académie Nationale de Médecine. https://doi.org/10.1016/j.banm.2020.05.042

Source records

crossref · retrieved 2026-09-26T04:43:29.665Z